CLGN

+ Watchlist + Portfolio

CollPlant Biotechnologies Ltd.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.57
52-Week Range: $2.64 – $26.80
Market Cap: $6.54M
P/E (TTM): —
EPS (TTM): -46.50
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.70
PEG Ratio: —
Return on Equity: -161.98%
Return on Assets: -62.95%
Gross Margin: 0.00%
Operating Margin: -2437.96%
Profit Margin: 0.00%
Current Ratio: 1.57
Debt/Equity: 0.90
Total Debt: $2.66M
Free Cash Flow: $-6.89M
Revenue Growth: -39.70%
Earnings Growth: —
Enterprise Value: $5.10M

CLGN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$299.00K	$10.96M	$515.00K	$2.37M
Cost of Revenue	$400.00K	$1.99M	$1.63M	$835.00K
Gross Profit	-$101.00K	$8.97M	-$1.11M	$1.54M
Research & Development	$10.26M	$10.48M	$10.52M	$8.19M
Selling, General & Admin	$6.74M	$6.00M	$5.63M	$4.83M
Operating Expenses	$17.00M	$16.48M	$16.14M	$13.02M
Operating Income	-$17.10M	-$7.51M	-$17.25M	-$11.48M
EBITDA	-$16.02M	-$6.41M	-$16.21M	-$10.57M
Pretax Income	-$16.93M	-$7.02M	-$16.61M	-$11.49M
Net Income	-$16.93M	-$7.02M	-$16.61M	-$11.49M
Diluted EPS	-1.53	-0.62	-1.45	-0.94
Diluted Shares	11.03M	11.39M	11.45M	12.20M

CLGN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$29.65M	$26.67M	$11.91M	$5.59M
Receivables	$552.00K	$393.00K	$583.00K	$224.00K
Inventory	$1.43M	$714.00K	$440.00K	$573.00K
Current Assets	$31.66M	$28.02M	$13.18M	$6.75M
Total Assets	$37.77M	$34.13M	$18.71M	$10.79M
Current Liabilities	$3.10M	$3.25M	$2.97M	$2.67M
Total Debt	$2.91M	$3.16M	$3.08M	$2.85M
Total Liabilities	$5.49M	$5.79M	$5.25M	$4.70M
Retained Earnings	-$89.72M	-$96.74M	-$113.35M	-$124.84M
Shareholders' Equity	$32.28M	$28.34M	$13.46M	$6.08M
Working Capital	$28.55M	$24.77M	$10.21M	$4.08M

CLGN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.70M	-$2.76M	-$14.09M	-$9.42M
Capital Expenditure	-$1.32M	-$954.00K	-$483.00K	-$28.00K
Free Cash Flow	-$15.01M	-$3.72M	-$14.58M	-$9.45M
Depreciation & Amortisation	$1.08M	$1.10M	$1.04M	$912.00K
Stock-Based Compensation	$2.17M	$1.94M	$1.72M	$999.00K
Investing Cash Flow	$28.92M	-$1.16M	-$539.00K	-$27.00K
Financing Cash Flow	$1.87M	$1.11M	$9.00K	$3.10M
Net Change in Cash	$17.10M	-$2.81M	-$14.62M	-$6.34M

CLGN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.06M	$179.00K	$77.00K	$60.00K	$73.00K
Cost of Revenue	$188.00K	$186.00K	$269.00K	$192.00K	$316.00K
Gross Profit	$1.87M	-$7.00K	-$192.00K	-$132.00K	-$243.00K
Research & Development	$2.10M	$2.01M	$2.09M	$1.98M	$1.68M
Selling, General & Admin	$1.41M	$1.16M	$1.23M	$1.04M	$1.19M
Operating Expenses	$3.52M	$3.17M	$3.31M	$3.02M	$2.87M
Operating Income	-$1.65M	-$3.18M	-$3.51M	-$3.15M	-$3.12M
EBITDA	-$1.40M	-$2.95M	-$3.28M	-$2.93M	-$2.90M
Pretax Income	-$1.45M	-$3.35M	-$3.48M	-$3.21M	-$3.10M
Net Income	-$1.45M	-$3.35M	-$3.48M	-$3.21M	-$3.10M
Diluted EPS	-0.13	-0.28	-0.27	—	-0.23
Diluted Shares	11.45M	11.84M	12.72M	—	13.75M

CLGN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$10.73M	$11.43M	$8.55M	$5.59M	$4.26M
Receivables	$440.00K	$364.00K	$254.00K	$224.00K	$233.00K
Inventory	$673.00K	$553.00K	$540.00K	$573.00K	$679.00K
Current Assets	$12.09M	$12.62M	$9.62M	$6.75M	$5.54M
Total Assets	$17.21M	$17.44M	$14.09M	$10.79M	$9.18M
Current Liabilities	$2.70M	$2.74M	$2.63M	$2.67M	$2.44M
Total Debt	$2.84M	$3.03M	$2.94M	$2.85M	$2.65M
Total Liabilities	$4.81M	$4.93M	$4.78M	$4.70M	$4.30M
Retained Earnings	-$114.80M	-$118.15M	-$121.63M	-$124.84M	-$127.94M
Shareholders' Equity	$12.40M	$12.51M	$9.30M	$6.08M	$4.89M
Working Capital	$9.39M	$9.88M	$6.99M	$4.08M	$3.10M

CLGN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.17M	-$2.44M	-$2.88M	-$2.94M	-$3.05M
Capital Expenditure	-$9.00K	-$3.00K	-$1.00K	-$15.00K	-$6.00K
Free Cash Flow	-$1.18M	-$2.44M	-$2.88M	-$2.95M	-$3.06M
Depreciation & Amortisation	$244.00K	$229.00K	$223.00K	$216.00K	$210.00K
Stock-Based Compensation	$382.00K	$353.00K	$282.00K	-$18.00K	$180.00K
Investing Cash Flow	-$8.00K	-$3.00K	-$1.00K	-$15.00K	-$6.00K
Financing Cash Flow	$0.00	$3.10M	$0.00	$0.00	$1.72M
Net Change in Cash	-$1.18M	$659.00K	-$2.88M	-$2.95M	-$1.34M

Market Snapshot

About

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company developing tissue-repair products based on its proprietary plant-derived recombinant human collagen (rhCollagen) technology. Headquartered in Rehovot, Israel, the company produces Type I collagen using genetically engineered tobacco plants, creating a non-animal, non-immunogenic alternative to traditional collagen sources. CollPlant's BioInk products are used in 3D bioprinting for organ and tissue regeneration, while its dermal and soft tissue fillers target the aesthetic medicine market. The company partners with medical device manufacturers and research institutions to advance its collagen platform across multiple therapeutic applications.